GoodRx Cuts Top End Of FY23 Total Revenue Outlook; Revises Guidance From $750M-$775M To $750M-$760M, Est. $762.25M
Portfolio Pulse from Benzinga Newsdesk
GoodRx has revised its FY23 total revenue outlook from $750M-$775M to $750M-$760M, which is below the estimated $762.25M. The company's CFO, Karsten Voermann, mentioned that their direct contracting approach with retailers may lead to a short-term headwind for prescription transactions revenue growth.
August 09, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
GoodRx's revised FY23 revenue outlook is lower than the estimated $762.25M, which may negatively impact the company's stock in the short term.
GoodRx's revised FY23 revenue outlook is lower than the estimated $762.25M. This could lead to a negative sentiment among investors, potentially causing a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100